Uterus Transplantation

These connections serve different functions in the graft. Reconnected blood vessels provide circulation to the transplanted uterus, while reconstruction of the reproductive tract creates the anatomical pathway needed for embryo implantation and gestation. Successful surgery therefore depends on restoring both vascular support and reproductive continuity, rather than treating the uterus as an isolated organ.

Immunosuppressive drugs are used to reduce the recipient’s immune response against the transplanted uterus and help prevent rejection. Their use is central to maintaining graft function while the uterus supports embryo implantation and pregnancy. Because these medicines create an ongoing clinical burden, researchers also evaluate whether the transplanted uterus can later be removed after a successful pregnancy.

The graft must remain functional after transplantation, with its blood supply and reproductive tract connections maintained well enough to support embryo implantation and gestation. Immunosuppression also plays an important role by limiting rejection. These interacting surgical and medical requirements explain why studies continue to assess both fertility outcomes and safety rather than pregnancy alone.

Uterus transplantation addresses infertility caused by the absence or loss of a functional uterus, often called uterine-factor infertility. Instead of relying only on treatments aimed at conception, it provides a uterine environment in which an embryo may implant and gestation may occur. This makes it relevant to selected patients whose infertility is specifically linked to uterine function.

The approach begins with placement of a healthy uterus from a living or deceased donor into a recipient. Surgeons then connect the graft’s blood vessels and reproductive tract, followed by immunosuppressive treatment to help prevent rejection. If the graft supports embryo implantation and gestation, the uterus may eventually be removed to reduce the need for prolonged immunosuppression.

Potential candidates are selected patients with uterine-factor infertility, including people born without a uterus and those who lost one through disease or surgery. The approach is therefore relevant when the absence of a functional uterus prevents gestation. Its use remains selective because clinical research continues to evaluate safety, fertility outcomes, and ethical considerations.

Research examines the safety of the surgical procedure, the effectiveness of immunosuppression, and fertility outcomes after transplantation. Investigators also consider the ethical issues associated with using a living or deceased donor organ and with potentially removing the graft after pregnancy. This broader evaluation helps determine the medical role of the approach for selected patients.

Removal may reduce the recipient’s need for long-term immunosuppressive drugs. Those medicines are required to help prevent rejection while the graft is functioning, but they also make transplantation a continuing medical intervention. If the uterus has fulfilled its intended reproductive role, removing it can limit the duration of immunosuppression, an issue evaluated in ongoing research.